Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PRS17

MLA

Johnson Agniswamy, et al. “Novel HIV PR Inhibitors with C4-Substituted Bis-THF and Bis-Fluoro-Benzyl Target the Two Active Site Mutations of Highly Drug Resistant Mutant PRS17.” Biochemical and Biophysical Research Communications, vol. 566, Aug. 2021, pp. 30–35. EBSCOhost, https://doi.org/10.1016/j.bbrc.2021.05.094.

APA

Johnson Agniswamy, Irene T. Weber, Arun K. Ghosh, & Daniel W. Kneller. (2021). Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PRS17. Biochemical and Biophysical Research Communications, 566, 30–35. https://doi.org/10.1016/j.bbrc.2021.05.094

Chicago

Johnson Agniswamy, Irene T. Weber, Arun K. Ghosh, and Daniel W. Kneller. 2021. “Novel HIV PR Inhibitors with C4-Substituted Bis-THF and Bis-Fluoro-Benzyl Target the Two Active Site Mutations of Highly Drug Resistant Mutant PRS17.” Biochemical and Biophysical Research Communications 566 (August): 30–35. doi:10.1016/j.bbrc.2021.05.094.